{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:55:43Z","timestamp":1791078943266,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,3,31]],"date-time":"2004-03-31T00:00:00Z","timestamp":1080691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> A 63\u2010year\u2010old man with therapy\u2010resistant S\u00e9zary syndrome was enrolled in a multicenter trial of oral bexarotene for advanced\u2010stage cutaneous T\u2010cell lymphoma (CTCL).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Monthly evaluations for efficacy and side\u2010effects were conducted and documented.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Gradual improvement in erythema, pruritus, and scale was noted during the initial 16\u2010week trial period and treatment was extended to 40\u00a0weeks. From week 20 to week 40, the erythroderma continued to improve and the lymph node burden decreased, but the absolute S\u00e9zary cell count inversely increased. By week 40, intractable pruritus and erythroderma abruptly recurred, and bexarotene was discontinued.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Bexarotene is well tolerated and can be efficacious in patients with S\u00e9zary syndrome. Shifting of S\u00e9zary cells between different compartments was noted. Further studies on the interaction between the skin, lymph nodes, and peripheral blood compartments during bexarotene treatment in this subset of patients with CTCL are needed.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2004.02132.x","type":"journal-article","created":{"date-parts":[[2004,12,24]],"date-time":"2004-12-24T20:43:28Z","timestamp":1103921008000},"page":"25-28","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral bexarotene in a therapy\u2010resistant S\u00e9zary syndrome patient: observations on S\u00e9zary cell compartmentalization"],"prefix":"10.1111","volume":"44","author":[{"given":"Rokea A.","family":"El\u2010Azhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia A.","family":"Bouwhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,12,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-78771-3_17"},{"key":"e_1_2_7_3_2","first-page":"276","article-title":"Mycosis fungoides and the S\u00e9zary syndrome","volume":"26","author":"Kim YH","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018214"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6928.551"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00044a014"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.15.7.3540"},{"key":"e_1_2_7_8_2","first-page":"1658","article-title":"A Phase I study of LGD1069 in adults with advanced cancer","volume":"5","author":"Rizvi NA","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.790"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90282-0"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1006\/scel.1994.1015"},{"key":"e_1_2_7_13_2","first-page":"649","article-title":"A new rexinoid for cutaneous T\u2010cell lymphoma","volume":"137","author":"Cheng SX","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_7_14_2","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early\u2010stage cutaneous T\u2010cell lymphoma","volume":"137","author":"Duvic M","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904083401404"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2004.02132.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2004.02132.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:33:55Z","timestamp":1696919635000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2004.02132.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,23]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1111\/j.1365-4632.2004.02132.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02132.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,23]]},"assertion":[{"value":"2004-12-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}